Citations

Showing 10 of 108119 citations.

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Chumsri, Saranya , Serie, Daniel, Li, Zhuo , Pogue–Geile, Katherine L. , Soyano‐Muller, Aixa E., Mashadi-Hossein, Afshin , Warren, Sarah , Lou, Yanyan , Colón‐Otero, Gerardo , Knutson, Keith L. , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Serie, Daniel J, Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | February 26, 2019 | Volume: 25 | Issue: 14 | Pages: 4422-4430

10.1158/1078-0432.ccr-18-2206 | PMID 30808774 Get It

Abstract Purpose: Young age has been shown to be an independent predictor of poor outcome in breast cancer. In HER2-positive breast cancer, the effects of aging remain largely unknown. Experimental Design: A total of 4,547 patients were included [3,132 from North Central Cancer Treatment Group (NCCTG) N9831 and 1,415 from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31]. Pathologic stromal tumor-infiltrating lymphocyte (sTIL) and molecular tumor infiltrating lymphocyte (mTIL) signatures were evaluated. Results: In NCCTG N9831, comparable benefit of trastuzumab was observed in all patients [age ≤ 40; HR, 0.43; 95% confidence interval (CI), 0.28–0.66; P < 0.001; and age > 40; HR, 0.56; 95% CI, 0.45–0.69; P < 0.001]. Similar results were observed in NSABP B-31 (age ≤ 40; HR, 0.45; 95% CI, 0.29–0.68; P < 0.001; and age > 40; HR, 0.42; 95% CI, 0.33–0.54; P < 0.001). Among patients who received chemotherapy alone, younger age was associated with poor outcome in the hormone receptor–positive subset, but not the hormone receptor–negative subset, in both trials. Although there was no association between sTILs and age, a small, but significant increase in mTIL CD45 and some immune subset signatures were observed. Among patients who received chemotherapy alone, patients over 40 years of age with lymphocyte-predominant breast cancer had excellent outcome, with 95% remaining recurrence free at 15 years. Conclusions: Among patients treated with trastuzumab, there was no significant difference in outcome related to age. Our study suggests that trastuzumab can negate the poor prognosis associated with young age.
Assessment of pulsatile insulin secretion derived from peripheral plasma C-peptide concentrations by nonparametric stochastic deconvolution
LAURENTI, MARCELLO C. , Vella, Adrian , Varghese, Ron T. , Andrews, James C. , Sharma, Anu , Kittah, Nana Esi, Rizza, Robert A., Matveyenko, Aleksey V. , Nicolao, Giuseppe De , Man, Chiara Dalla , Matveyenko, Aleksey, Dalla Man, Chiara , Vella, Adrian , Cobelli, Claudio

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | February 26, 2019 | Volume: 316 | Issue: 5 | Pages: E687-E694

10.1152/ajpendo.00519.2018 | PMID 30807214 Get It

The characteristics of pulsatile insulin secretion are important determinants of type 2 diabetes pathophysiology, but they are understudied due to the difficulties in measuring pulsatile insulin secretion noninvasively. Deconvolution of either peripheral C-peptide or insulin concentrations offers an appealing alternative to hepatic vein catheterization. However, to do so, there are a series of methodological challenges to overcome. C-peptide has a relatively long half-life and accumulates in the circulation. On the other hand, peripheral insulin concentrations reflect relatively fast clearance and hepatic extraction as it leaves the portal circulation to enter the systemic circulation. We propose a method based on nonparametric stochastic deconvolution of C-peptide concentrations, using individually determined C-peptide kinetics, to overcome these limitations. The use of C-peptide (instead of insulin) concentrations allows estimation of portal (and not post-hepatic) insulin pulses, whereas nonparametric stochastic deconvolution allows evaluation of pulsatile signals without any a priori assumptions of pulse shape and occurrence. The only assumption required is the degree of smoothness of the (unknown) secretion rate. We tested this method first on simulated data and then on 29 nondiabetic subjects studied during euglycemia and hyperglycemia and compared our estimates with the profiles obtained from hepatic vein insulin concentrations. This method produced satisfactory results both in the ability to fit the data and in providing reliable estimates of pulsatile secretion, in agreement with hepatic vein measurements. In conclusion, the proposed method enables reliable and noninvasive measurement of pulsatile insulin secretion. Future studies will be needed to validate this method in people with type 2 diabetes.
Milestone prediction for time‐to‐event endpoint monitoring in clinical trials
Heller, Martin , Shi, Qian , Heller, Martin , Shi, Qian , Ou, Fang‐Shu

Mayo Clinic

Pharmaceutical Statistics | February 26, 2019 | Volume: 18 | Issue: 4 | Pages: 433-446

10.1002/pst.1934 | PMID 30806485 Get It

Predicting the times of milestone events, ie, interim and final analyses in clinical trials, helps resource planning. This manuscript presents and compares several easily implemented methods for predicting when a milestone event is achieved. We show that it is beneficial to combine the predictions from different models to craft a better predictor through prediction synthesis. Furthermore, a Bayesian approach provides a better measure of the uncertainty involved in prediction of milestone events. We compare the methods through two simulations where the model has been correctly specified and where the models are a mixture of three incorrectly specified model classes. We then apply the methods on two real clinical trial data, North Central Cancer Treatment Group (NCCTG) N0147 and N9841. In summary, the Bayesian prediction synthesis methods automatically perform well even when the data collection is far from homogeneous. AnRshiny app is under development to carry out the prediction in a user‐friendly fashion.
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
Tassorelli, Cristina , Ashina, Messoud , Becker, Werner J. , Ferrari, Michel D. , Goadsby, Peter J. , Wang, Shuu‐Jiun , Mandrekar, Jay , Goadsby, Peter J , Wang, Shuu-Jiun , Ashina, Messoud , Diener, Hans‐Christoph , Dodick, David W. , Silberstein, Stephen D. , Lipton, Richard B. , Pozo‐Rosich, Patricia

Mayo Clinic

Cephalalgia | February 26, 2019 | Volume: 39 | Issue: 6 | Pages: 687-710

10.1177/0333102419828967 | PMID 30806518 Get It

The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. Scientific and clinical developments in headache medicine led to second and third editions in 2000 and 2012, respectively. The current, fourth edition of the Guidelines retains the structure and much content from previous editions. However, it also incorporates evidence from clinical trials published after the third edition as well as feedback from meetings with regulators, pharmaceutical and device manufacturers, and patient associations. Its final form reflects the collective expertise and judgement of the Committee. These updated recommendations and commentary are intended to meet the Society's continuing objective of providing a contemporary, standardized, and evidence-based approach to the conduct and reporting of randomised controlled trials for the acute treatment of migraine attacks.
Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot
Egbe, Alexander C. , Miranda, William R. , Ammash, Naser M., Missula, Venkata, Jadav, Raja, Najam, Maria , Kothapalli, Srikanth, Connolly, Heidi M. , Missula, Venkata R

Mayo Clinic

Journal of the American Heart Association | February 26, 2019 | Volume: 8 | Issue: 5 | Pages: No page available

10.1161/jaha.118.011474 | PMID 30803288 Get It

Background Available outcomes data for anticoagulation therapy in adults with congenital heart disease ( CHD ) provide assessment of global risk of this therapy for CHD patients (a heterogeneous population), but the risk of complications for the different CHD diagnoses is unknown. The purpose of the study was to describe the indications for anticoagulation, and the incidence and risk factors for major bleeding complication in adults with tetralogy of Fallot. Methods and Results We queried Mayo Adult Congenital Heart Disease (MACHD) database for tetralogy of Fallot patients (aged ≥18 years) that received anticoagulation, 1990–2017. Of 130 patients (42±14 years, 75 men [58%]), warfarin and direct oral anticoagulants were used in 125 (96%) and 5 (4%), respectively because atrial arrhythmias (n=109), mechanical prosthetic valve (n=29), intracardiac thrombus (n=4), pulmonary embolism (n=6), stroke (n=3), and perioperative anticoagulation (n=44). The median hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score for the entire cohort was 1 (0–2) and 27 (21%) had hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2. There were 14 minor bleeding events (1.6% per year) and 11 major bleeding events (1.3% per year) in 8 patients during median follow‐up of 74 months (856 patient‐years). Mechanical prosthesis (hazard ratio 1.78, CI 1.29–3.77, P =0.021) and hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2 (hazard ratio 1.41, CI 1.03–3.88, P =0.046) were risk factors for major bleeding events. All‐cause mortality was higher in patients with major bleeding events (n=6, 75%) compared with patients without major bleeding events (n=25, 21%), P =0.001. Conclusions Considering the heterogeneity of the CHD population, data from the current study may be better suited for clinical decision‐making in tetralogy of Fallot patients.
Recommendations on the Use of Ultrasound Guidance for Adult Abdominal Paracentesis: A Position Statement of the Society of Hospital Medicine
Cho, Joel, Jensen, Trevor, Reierson, Kreegan , Mathews, Benji K., Bhagra, Anjali , Franco‐Sadud, Ricardo, Grikis, Loretta, Mader, Michael , Dancel, Ria , Lucas, Brian , Soni, Nilam J. , Tierney, David M. , Arntfield, Robert , Soni, Nilam J

Mayo Clinic

Journal of Hospital Medicine | February 26, 2019 | Volume: 14 | Issue: 1 | Pages: No page available

10.12788/jhm.3095 | PMID 30604780 Get It

EXECUTIVE SUMMARY We recommend that ultrasound guidance should be used for paracentesis to reduce the risk of serious complications, the most common being bleeding. We recommend that ultrasound guidance should be used to avoid attempting paracentesis in patients with an insufficient volume of intraperitoneal free fluid to drain. We recommend that ultrasound guidance should be used with paracentesis to improve the success rates of the overall procedure. We recommend that ultrasound should be used to assess the volume and location of intraperitoneal free fluid to guide clinical decision making of where paracentesis can be safely performed. We recommend that ultrasound should be used to identify a needle insertion site based on size of the fluid collection, thickness of the abdominal wall, and proximity to abdominal organs. We recommend that the needle insertion site should be evaluated using color flow Doppler ultrasound to identify and avoid abdominal wall blood vessels along the anticipated needle trajectory. We recommend that a needle insertion site should be evaluated in multiple planes to ensure clearance from underlying abdominal organs and detect any abdominal wall blood vessels along the anticipated needle trajectory. We recommend that a needle insertion site should be marked with ultrasound immediately before performing the procedure, and the patient should remain in the same position between marking the site and performing the procedure. We recommend that using real‐time ultrasound guidance for paracentesis should be considered when the fluid collection is small or difficult to access. We recommend that dedicated training sessions, including didactics, supervised practice on patients, and simulation‐based practice, should be used to teach novices how to perform ultrasound‐guided paracentesis. We recommend that simulation‐based practice should be used, when available, to facilitate acquisition of the required knowledge and skills to perform ultrasound‐ guided paracentesis. We recommend that competence in performing ultrasound‐guided paracentesis should be demonstrated prior to independently performing the procedure on patients.
Point‐of‐Care Ultrasound for Hospitalists: A Position Statement of the Society of Hospital Medicine
Soni, Nilam J. , Schnobrich, Daniel, Mathews, Benji K., Tierney, David M. , Jensen, Trevor, Dancel, Ria , Cho, Joel, Dversdal, Renee K. , Mints, G. E. , Bhagra, Anjali , Reierson, Kreegan , Kurian, Linda M. , Liu, Gigi , Candotti, Carolina, LoPresti, Charles M. , Wong, Tanping , Johnson, Gordon E., Maw, Anna , Franco‐Sadud, Ricardo, Lucas, Brian , Boesch, Brandon, Lenchus, Joshua D. , Soni, Nilam J

Mayo Clinic

Journal of Hospital Medicine | February 26, 2019 | Volume: 14 | Issue: 1 | Pages: No page available

10.12788/jhm.3079 | PMID 30604779 Get It

Many hospitalists incorporate point‐of‐care ultrasound (POCUS) into their daily practice to answer specific diagnostic questions or to guide performance of invasive bedside procedures. However, standards for hospitalists in POCUS training and assessment are not yet established. Most internal medicine residency training programs, the major pipeline for incoming hospitalists, have only recently begun to incorporate POCUS in their curricula. The purpose of this document is to inform a broad audience on what POCUS is and how hospitalists are using it. This document is intended to provide guidance for the hospitalists who use POCUS and administrators who oversee its use. We discuss POCUS 1) applications, 2) training, 3) assessments, and 4) program management. Practicing hospitalists must continue to collaborate with their local credentialing bodies to outline requirements for POCUS use. Hospitalists should be integrally involved in decision‐making processes surrounding POCUS program management.
Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever
Bajaj, Jasmohan S. , Wong, Florence , Kamath, Patrick S. , Wong, Florence

Mayo Clinic

Hepatology | February 26, 2019 | Volume: 70 | Issue: 1 | Pages: 450-451

10.1002/hep.30589 | PMID 30805952 Get It

Sustained exercise hyperemia during prolonged adenosine infusion in humans
Ranadive, Sushant M. , Shepherd, John R. A. , Curry, Timothy B. , Dinenno, Frank A. , Joyner, Michael J. , Ranadive, Sushant

Mayo Clinic

Physiological Reports | February 26, 2019 | Volume: 7 | Issue: 4 | Pages: e14009

10.14814/phy2.14009 | PMID 30806018 Get It

Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study
Eirin, Alfonso , Herrmann, Sandra M. , Saad, Ahmed , Abumoawad, Abdelrhman , Textor, Stephen C., Lerman, Lilach O. , Herrmann, Sandra M , Eirin, Alfonso , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Acta Physiologica | February 26, 2019 | Volume: 226 | Issue: 3 | Pages: No page available

10.1111/apha.13267 | PMID 30803138 Get It

AbstractAimsPatients with renovascular hypertension (RVH) exhibit elevated urinary mtDNA copy numbers, considered to constitute surrogate markers of renal mitochondrial injury. The modest success of percutaneous transluminal renal angioplasty (PTRA) in restoring renal function in RVH has been postulated to be partly attributable to acute reperfusion injury. We hypothesized that mitoprotection during revascularization would ameliorate PTRA–induced renal mitochondrial injury, reflected in elevated urinary mtDNA copy numbers and improve blood pressure and functional outcomes 3 months later.MethodsWe prospectively measured urinary copy number of the mtDNA genes COX3 and ND1 using qPCR in RVH patients before and 24 hrs after PTRA, performed during IV infusion of vehicle (n = 8) or the mitoprotective drug elamipretide (ELAM, 0.05 mg/kg/h, n = 6). Five healthy volunteers (HV) served as controls. Urinary mtDNA levels were also assessed in RVH and normal pigs (n = 7 each), in which renal mitochondrial structure and density were studied ex‐vivo.ResultsBaseline urinary mtDNA levels were elevated in all RVH patients vs HV and directly correlated with serum creatinine levels. An increase in urinary mtDNA 24 hours after PTRA was blunted in PTRA+ELAM vs PTRA+Placebo. Furthermore, 3‐months after PTRA, systolic blood pressure decreased and estimated glomerular filtration rate increased only in ELAM–treated subjects. In RVH pigs, mitochondrial damage was observed using electron microscopy in tubular cells and elevated urinary mtDNA levels correlated inversely with renal mitochondrial density.ConclusionsPTRA leads to an acute rise in urinary mtDNA, reflecting renal mitochondrial injury that in turn inhibits renal recovery. Mitoprotection might minimize PTRA–associated mitochondrial injury and improve renal outcomes after revascularization.